Comparison ear injury in Gentamicin and Amikacin in neonates

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017071920258N54

Enrollment

160

Registered

2017-08-07

Start date

2016-01-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ear damage. Ototoxic hearing loss

Interventions

Intervention 1: Intervention group: We prescribe neonate with Ampicillin and Amikacin. Intervention 2: Intervention group: We prescribe neonate with Ampicillin and Gentamicin.

Treatment - Drugs

Intervention group: We prescribe neonate with Ampicillin and Amikacin.

Intervention group: We prescribe neonate with Ampicillin and Gentamicin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Neonates admitted to Amirkabir and Taleghani hospitals in Arak with an indication ?of antibiotic therapy with aminoglycosides Exclusion criteria: cognitive and congenital hearing and ear diseases; history of receiving ototoxic ?drugs (especially Gentamicin and Amikacin); underlying congenital diseases such ?as kidney disorders, urinary tract and tubular

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hearing test. Timepoint: after one months. Method of measurement: Auditory brainstem response.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzad Zamani

Arak University of Medical Sciences

zamani@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026